Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Yanan Zhu maintains a Buy rating on Atrium Therapeutics (RNA) with a $25 price target, despite shares closing at $12.30. The consensus remains Strong Buy with an average target of $25. Additionally, TipRanks launched the RANK ETF on NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies.
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Atrium Therapeutics, Inc., with a price target of $25.00. The company’s shares closed yesterday at $12.30.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Zhu is a 5-star analyst with an average return of 16.0% and a 39.02% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, BeOne Medicines, and enGene Holdings.
Currently, the analyst consensus on Atrium Therapeutics, Inc. is a Strong Buy with an average price target of $25.00.